Le Lézard
Classified in: Health, Science and technology
Subject: FVT

DiamiR Announces Participation at 2018 Alzheimer's Association International Conference


MONMOUTH JUNCTION, N.J., July 19, 2018 /PRNewswire/ -- DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that it will exhibit at the Alzheimer's Association International Conference to be held in Chicago, IL on July 22-26, 2018.

At the DiamiR booth, #713 in Hall F1 of McCormick Place, the company staff will meet with the conference attendees to discuss DiamiR's targeted approach to early detection, differential diagnosis, and monitoring of neurodegenerative diseases based on the quantitative analysis of brain-enriched microRNAs circulating in plasma. Dr. Kira Sheinerman, Chief Executive Officer, and Jennifer Seibert, Strategic Development, will provide updates on the ongoing and planned projects and discuss collaborative opportunities.

About Alzheimer's Association International Conference
The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.

About DiamiR
DiamiR Biosciences is a privately held molecular diagnostics company focused on developing minimally invasive tests for mild cognitive impairment, Alzheimer's disease, and other conditions. The proprietary technology is based on quantitative analysis of organ-enriched microRNA signatures in plasma and is being developed for early diagnosis, patient stratification, as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic centers, disease foundations, and pharma companies. For more information, please visit the company's website at www.diamirbio.com.

Contact:
Kira Sheinerman, PhD, MBA
CEO
917-678-0990
[email protected] 

Please Note: This news release contains forward-looking statements regarding future events. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially.

SOURCE DiamiR


These press releases may also interest you

at 02:54
HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the Nature...

at 02:50
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany?Universitätsklinikum Tübingen...

at 02:24
Today, 23 April 2024, the subscription period in SciBase Holding AB (publ) ('SciBase' or the 'Company') rights issue of units of up to approximately SEK 15 million commences (the 'Rights Issue'). The Rights Issue was resolved by the Board of...

at 02:05
Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A...

at 02:00
Red Arrow Therapeutics Inc. closed a $4.5M Seed Extension round, raising from four, top-tier institutional investors in Japan. Participants of this round are: Beyond Next Ventures Inc.The University of Tokyo Edge Capital Partners Co., Ltd.Keio...

at 01:05
Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care...



News published on and distributed by: